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Navneet S. Majhail,1,2 Elizabeth A. Murphy,3 Nancy A. Omondi,3 Pam Robinett,3
James L. Gajewski,4 C. Fred LeMaistre,5 Dennis Confer,3 J. Douglas Rizzo6,7Shortage of manpower and center capacity is expected to be a major challenge to the anticipated future
growth in the utilization of allogeneic hematopoietic cell transplantation (HCT) in the United States. Using
data from the National Marrow Donor Program’s Transplant Center Network Renewal Survey, we describe
transplant center and transplant physician capacity in the United States from 2005 to 2009. Over this 5-year
period, the number of allogeneic transplants increased by 30%, bed capacity increased by 17%, and physician
full-time equivalents increased by 26%. The number of related donor HCT increased by 15% and unrelated
donor HCT increased by 45%. In addition to large centers, small- and medium-sized centers also made a ma-
jor contribution to overall national transplant volumes for both related and unrelated donor HCT. Increase in
utilization of unrelated donor HCToccurred in centers irrespective of their size. The majority of transplant
centers were performing more transplantations using existing physician and bed capacity. Our study provides
important descriptions of allogeneic transplant activity and capacity of U.S. centers, and our data will assist
policy makers plan for the projected growth in the use of transplantation.
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Physician capacityINTRODUCTION
The utilization of related and unrelated donor
allogeneic hematopoietic cell transplantation (HCT)
has markedly increased over the past decade. This
has resulted from advancements in transplantation
technology and supportive care, introduction of non-
myeloablative and reduced-intensity conditioning
(RIC) regimens, availability of a larger number of
unrelated donors, expanding use of alternative graft
sources, and emerging indications of transplantation.1Blood and Marrow Transplant Program, University of
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6/j.bbmt.2011.03.008The National Marrow Donor Program (NMDP)
projects that over the next 5 years, it will double the
annual number of unrelated donor transplants includ-
ing umbilical cord blood transplants it facilitates from
approximately 5000 in 2010 to 10,000 by 2015. As
more patients benefit from transplantation, there is
concern that U.S. healthcare capacity is insufficient
to accommodate the anticipated growth in allogeneic
HCT activity. Availability of transplant physicians,
other medical providers, and adequate infrastructure
is expected to be a major barrier to the projected ex-
pansion of transplantation. Recent studies performed
by the American Society of Blood and Marrow Trans-
plantation (ASBMT) have projected a shortage of
transplant physicians and transplant center capacity
in the United States [1,2]. In planning for future
growth, it is essential that we understand the present
capacity for HCT in this country. In this report, we
describe the prevailing transplant center and
transplant physician capacity in the United States,
using data collected by the NMDP’s Transplant
Center Network Renewal Survey.METHODS
The Transplant Center Network Renewal Survey
is administered annually by the NMDP to all centers
Biol Blood Marrow Transplant 17:956-961, 2011 957U.S. Transplant Capacityin its network to ensure that centers are in compliance
with NMDP Standards and Participation Criteria.
The survey inquires about staff resources and center
facilities for allogeneic HCT and has been adminis-
tered electronically using a Web-based instrument
since 2004. Each year, centers complete the survey in
the calendar month they joined the NMDP network.
In 2009, 128 centers in the United States participated
in the NMDP network and performed a median of 31
(range: 2-313) allogeneic transplants/center. For this
study, we used information provided by centers in
the United States that participated in the network be-
tween 2005 and 2009 about their annual allogeneic
transplant volume (using related or unrelated donors),
center transplant bed capacity, and full-time equiva-
lent (FTE) transplant physician positions.
Our study was designed as a descriptive study; data
were summarized as frequencies/proportions or
median/range, as appropriate. Unrelated donor allo-
geneic HCT volumes described include both adult
volunteer unrelated donor and umbilical cord blood
HCT. The unit of measure in our analysis is the
number of transplants; an individual patient may
have received more than 1 HCT. Also, volumes
reported include transplants facilitated by any registry,
NMDP, or other. The latter represent a relatively
small volume of unrelated donor transplant activity
in the country; in 2009, 9% of all unrelated donor
transplants performed in the United States were facil-
itated by donor registries other than the NMDP.RESULTS
Growth in Center Capacity and Allogeneic HCT
Activity
In 2009, 128 transplant centers in theUnited States
participated in theNMDPnetwork comparedwith 113Table 1. Transplant Bed Capacity, Physician FTEs, and Allogeneic
between 2005 and 2009
Characteristic 2005 2006
Centers, N 113 119
Transplant bed capacity 1937 2024
Median beds/center (range) 16 (2-56) 14 (2-56)
Transplant physician FTEs 750 796
Median FTE/center (range) 5 (1-49) 5 (1.5-46)
Number of allogeneic HCT (any donor) 4578 4960
Median HCT/center (range) 25 (1-286) 28 (3-285)
Number of related donor HCT 2342 2587
Median HCT/center (range) 12 (1-154) 15 (1-127)
Number of unrelated donor HCT 2236 2373
Median HCT/center (range) 10 (0-152) 11 (1-158)
Allogeneic HCT/HCT bed 2.4 2.5
Allogeneic HCT/Physician FTE 6.1 6.2
HCT Bed/Physician FTE 2.6 2.5
FTE indicates full-time equivalent; HCT, hematopoietic cell transplantation.in 2005 (Table 1). Collectively, these 128 centers re-
ported 5947 allogeneic transplants (related donor:
2696; unrelated donor: 3251) and represented 2264
transplant beds and 943 transplant physician FTEs.
Compared with 2005, this translated into a 30% in-
crease in allogeneic transplant activity (annual growth
rate of 6%), a 17% increase in transplant bed capacity,
and a 26%increase inphysicianFTEs.Growth in trans-
plant volumewas a result of increase in both related and,
more notably, unrelated donor HCT (Figure 1). The
number of related donor HCT increased by 15% and
unrelated donor HCT increased by 45%.
During this time period, 110 centers participated
in the network for all 5 years, while 19 centers joined
and 4 centers withdrew from the network. The 4
centers that withdrew were small centers and
performed a median of 7 allogeneic transplants (range:
1-9) annually. Attrition of these centers resulted in
a net loss of 33 transplant beds. In general, the 19
centers that joined the network were also relatively
small; in the calendar year following the year in which
they became members (because centers do not submit
an annual survey in the year of joining the network),
these centers performed a median of 14 allogeneic
transplants (range: 3-59) and contributed a median of
9 beds/center (range: 4-24) and a median of 3.75
physician FTEs/center (range: 2-24). Of note, these
19 centers were not necessarily ‘‘new’’ centers, but
had joined the network by virtue of their interest in
accessing unrelated donors through the NMDP.
Growth in transplant activity was largely contrib-
uted by centers that were members of the network
since at least 2005 (ie, all 5 years of the study period)
and by increase in transplantation of NMDP-facili-
tated unrelated donor grafts (Figure 1). Collectively
for the 110 such centers that remained in the network
for all 5 years, the number of all allogeneic transplants
increased by 18% from 2005 to 2009; the growth rateTransplant Volumes for U.S. Centers in the NMDP Network
Year
Change 2005
to 2009 (%)2007 2008 2009
121 125 128 +13.3%
2034 2172 2264 +16.9%
13 (2-56) 14 (2-65) 14 (2-73)
856 910 943 +25.7%
5 (1.5-47) 5 (1.5-47) 5 (2-47)
5148 5532 5947 +29.9%
25 (2-252) 30 (2-298) 31 (2-313)
2430 2610 2696 +15.1%
12 (1-122) 14 (1-144) 15 (1-141)
2718 2922 3251 +45.4%
13 (0-141) 14 (0-154) 16 (0-172)
2.5 2.6 2.6 +8.3%
6.0 6.1 6.3 +3.3%
2.4 2.4 2.4 28.3%
Figure 1. Allogeneic HCTactivity among U.S. centers in the NMDP network between 2005 and 2009. Growth in allogeneic HCT volumewas primarily
attributed to an increase in NMDP-facilitated unrelated donor transplants in centers that were members of the network since at least 2005.
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lated donor transplants, it was 36% for this time pe-
riod. During this time period, these centers increased
their bed capacity by 6% (N5 101 beds) and physician
FTEs by 13% (N 5 94 FTEs). Similarly, of the 1369
additional allogeneic transplants that were performed
in 2009 compared with 2005, only 351 (26%) were
performed in centers that had newly joined the
network. However, growth in beds and physician
FTEs was largely contributed by new centers in the
network, which comprised 72% of additional beds
(N 5 226 beds) and 51% of additional physician
FTEs (n 5 99 FTEs) in 2009 compared with 2005
(Figure 2).Center Size and Transplant Capacity
We arbitrarily classified centers as small (#10
transplant beds), medium (11-20 transplant beds),
large (21-30 transplant beds), or very large ($31Figure 2. Contribution of existing and newNMDP network centers on
growth in allogeneic transplant activity, transplant beds, and physician
FTEs from 2005 to 2009.transplant beds) for the purposes of this study. In
2009, there were 40 small, 46 medium, 26 large, and
16 very large transplant centers (Figure 3). Of the
5,947 allogeneic HCT reported that year, these
centers represented 11%, 28%, 25%, and 36% trans-
plants, respectively. Irrespective of size, most centers
performed more unrelated than related donor trans-
plants; of their total transplant volume, the propor-
tion of unrelated donor transplants was 56%, 53%,
56%, and 55% for small, medium, large, and very
large sized centers, respectively.
We also explored the role of center size in change
in center capacity from 2005 to 2009 among the 110
centers that participated in the network for all 5 years.
Because the number of beds in a center could have
changed over time, we used the number of transplant
beds in a center in the year 2007 (middle of the study
time period) to assign center size for this analysis.
Using this criterion, we categorized center size as small
(N5 32), medium (N5 43), large (N 5 22), and very
large (N 5 13). For centers in each category, theFigure 3. Scatter plot of number of allogeneic HCT versus number of
transplant beds among U.S. centers in the NMDP network in 2009.
Biol Blood Marrow Transplant 17:956-961, 2011 959U.S. Transplant Capacitymedian annual growth rate of transplants/center was
5% (interquartile range [IQR], 23% to 20%) among
small, 6% (IQR, 1% to 11%) among medium, 1%
(IQR, –4% to 7%) among large, and 1% (IQR, 23
to 12%) among very large centers. Increase in trans-
plant activity at all centers over time was largely the re-
sult of more patients receiving unrelated donor HCT.
The median annual growth rate/center for related do-
nor HCT was 0%, 2%, 1%, and 23%, whereas that
for unrelated donor HCT was 8%, 8%, 2%, and 6%
for centers in the small, medium, large, and very large
size categories, respectively.
Figure 4 shows trends in various center capacity
metrics based on center size. Although the annual
growth rate was higher in small- to medium-sized cen-
ters, the increase in absolute number of patients receiv-
ing allogeneic transplants was greater in very large
centers. For instance, themedian number of allogeneic
HCT in small centers increased from 12/center in
2005 to 20/center in 2009 (67% increase). In compar-
ison, the median number of allogeneic HCT in very
large centers increased from 109/center to 143/center
(31% increase).
Physician Workforce and Transplant Capacity
The large and very large centers increased the
number of physician FTEs during this time period.Figure 4. Center size and (A) median number of allogeneic HCT/center, (B) m
allogeneic HCT/bed, and (D) median number of allogeneic HCT/physician FTE
network for all 5 years.Individual physicians were taking care of a larger
number of transplant recipients in large and very large
centers compared with small- and medium-sized cen-
ters, and this did not appear to change significantly
over time (Figure 4). In 2009, the median number of
allogeneic HCT per physician FTE was 4.7, 6.0, 7.4,
and 7.7 for small, medium, large, and very large cen-
ters, respectively. The majority of centers increased
the number of transplantations performed for each
transplant bed. We did not observe any clear correla-
tion between changes in center bed capacity or number
of physician FTEs and allogeneic transplant activity,
and a large number of centers were performing more
transplantations using existing beds and physicians.
Adult versus Pediatric Center Capacity
In the NMDP survey, centers self-report patient
population treated as adult-only, pediatric-only, or
combined adult and pediatric. For the year 2009, we
examined the center transplant activity, bed capacity
and physician FTEs based on this characteristic
(Table 2). There were 52 centers that identified them-
selves as adult-only transplant programs, 27 as pediat-
ric-only programs, and 49 as both adult and pediatric
programs. For each physician FTE, adult-only centers
and both adult and pediatric centers performed more
allogeneic transplants compared with pediatric-onlyedian number of transplant physician FTEs/center, (C) median number of
. This analysis was limited to 110 centers that participated in the NMDP
Table 2. Transplant Bed Capacity, Physician FTEs, and Allogeneic Transplant Volumes by Patient Population Treated for U.S.
Centers in the NMDP Network in 2009
Characteristic
Patient Population Treated in 2009*
Adult-Only Both Adult and Pediatric Pediatric-Only
Centers, N 52 49 27
Transplant bed capacity 781 1239 244
Median beds/center (range) 13 (3-31) 22 (8-56) 8 (2-24)
Transplant physician FTEs 244 581 118
Median FTE/center (range) 4 (2-13) 9 (3-47) 4 (2-9)
Number of allogeneic HCT (all donors) 1703 3737 507
Median HCT/center (range) 27 (2-118) 52 (4-313) 17 (3-60)
Allogeneic HCT/HCT bed 2.2 3.0 2.1
Allogeneic HCT/Physician FTE 7.0 6.4 4.3
FTE indicates full time equivalent; HCT, hematopoietic cell transplantation.
*Centers self-reported patient population treated as adult-only, pediatric-only, or both adult and pediatric; combined centers may have separate adult
and pediatric transplant physicians and beds, but are members of the NMDP network as a combined program.
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FTE). Of note, the 49 centers that reported treating
both adult and pediatric centers may not be ‘‘true’’
combined programs. For instance, an institution may
have separate adult and pediatric transplant units and
physicians and providers, but may have identified itself
as a combined program for purposes of NMDP
network membership.DISCUSSION
Among centers in the NMDP network, the
increasing utilization of allogeneic HCT in the United
States has been driven by a greater number of patients
receiving unrelated donor transplants. Besides factors
that have led to an increase in the use of allogeneic
HCT in general, the growth in unrelated donor
HCT reflects greater comfort level among centers in
using unrelated donor grafts and the better availability
of suitable unrelated donors [3]. The growth rate of
unrelated donor HCT can be expected to increase
even further as the utilization of umbilical cord blood
as a graft source becomes prevalent [4,5].
Optimal care of transplant recipients requires
availability of an adequate number of transplant physi-
cians. In 2009, centers reported a total of 943 physician
FTEs on the survey. In comparison, Gajewski et al. [1]
reported 1115 transplant physicians in the United
States in 2009 in a workforce study that used ASBMT
membership data. The inconsistency in the number of
transplant physicians from 2 sources can be explained
by the fact that some physicians do not work full-
time, and the ASBMTmembership roster may also in-
clude physicians who are not actively involved in the
clinical care of transplant recipients or practice in cen-
ters that do not participate in the NMDP network. Al-
beit some limitations, we noted that adult HCT
physicians treat a greater number of patients/physician
compared with pediatric physicians. When autologoustransplants are considered, this difference may be fur-
ther accentuated because autologous transplants are
more prevalent in the adult patient population and
our study did not account for autologous HCT.
Physicians without formal training in HCT (eg,
hospitalists) and providers other than physicians may
also play a major role as centers expand or plan for
future expansion of their capacities. Many centers
employ physician extenders or midlevel providers
(eg, nurse practitioners, physician assistants) to assist
in the care of HCT recipients [2]. We could not
address the utilization of physician extenders in the
care of transplant recipients in our study because the
survey has not collected these data. The present num-
ber and future availability of physician extenders and
their role in different models of care delivery in centers
will have to be considered as the transplant community
addresses transplant physician shortages.
Our study shows that the majority of NMDP
participating centers are doing more allogeneic
transplants, especially unrelated donor HCT,
irrespective of their size and without substantially
increasing their transplant beds or physician FTEs.
These trends raise many questions. Are centers
stretching existing resources to perform more trans-
plantations or are they more efficiently transplanting
patients using present capacity? Especially in the for-
mer case, is there a potential to compromise quality
of care and outcomes for HCT recipients? What is
the optimal number of transplantations that can be
performed per transplant bed or physician FTE?
What role do nontransplant physicians (eg, hospital-
ists) and nonphysician providers (eg, nurse practi-
tioners, physician assistants) play in addressing
capacity challenges in centers?
The NMDP projects that the number of unrelated
donor and cord blood transplants that it facilitates will
double from the present utilization of approximately
5000 transplants/year to 10,000 transplants/year in
2015. If these trends hold true, will centers have to
Biol Blood Marrow Transplant 17:956-961, 2011 961U.S. Transplant Capacitymake major changes and expenditures to accommo-
date these changes?What type and magnitude of facil-
ities, resources, and manpower will centers require?
What will be the role of nonphysician providers in
addressing physician shortages? What innovative
delivery of care models will provide the most efficient
posttransplant care to patients? Howwill centers coor-
dinate the long-term care of an increasing population
of transplant survivors with complex medical care
needs? As centers address capacity needs, they will
also have to consider disparities in access to transplan-
tation [6]. These important questions will have to be
considered as policy makers evaluate various methods
to address projected shortages of HCT workforce
and capacity. Given the diversity of centers in the
country with respect to size and resources, a multitude
of strategies will be required to meet individual center
needs for growth and expansion.
Our analysis has some limitations. First, the
Transplant Center Network Renewal Survey is an
administrative survey and center responses are not
audited for accuracy. For 2009, we compared the num-
ber of allogeneic transplants reported by centers on the
survey with those reported to the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR). The Transplant Center Network
Renewal Survey captured 89% of allogeneic HCT
activity among NMDP network centers in the United
States for 2009. Also, beds and physicians at transplant
centers typically are not exclusive for allogeneic HCT
and most likely represent resources that are shared
with autologous HCT recipients, or even other hospi-
talized patients. The relatively small volume of alloge-
neic HCT at some large and very large centers may be
secondary to large number of autologous transplants
being performed at those centers. We could not
account for autologous transplant activity because
the survey does not collect this information. Finally,
we could not consider individual center level changes
(eg, changes in models of care, center reorganization)
that may have impacted changes in transplant activity,
beds, or physician FTEs over time.
Our study provides important descriptions of allo-
geneic transplant activity and transplant center bed
and physician capacity of U.S. centers. Our data will
help policy makers, at both the national and institu-tional levels, to plan for the anticipated growth in
transplantation. The NMDP in collaboration with
the ASBMT and other stakeholders and experts has or-
ganized a multiyear symposium, ‘‘HSCT in 2020: Sys-
tem Capacity Initiative,’’ that will evaluate long-term
transplant capacity challenges and personnel shortages
and will suggest recommendations to address them.ACKNOWLEDGMENTS
We thank Emilie Clancy from Membership Ser-
vices, NationalMarrowDonor Program, for providing
data from the Transplant Center Network Renewal
Survey. We also acknowledge Ellen Denzen, Shaveta
Nayyar, and Tammy Payton from the Center
for International Blood and Marrow Transplant
Research—Patient Services Health Services Research
Program for their assistance with this study.
Financial disclosure: The CIBMTR is supported by
Public Health Service Grant/Cooperative Agreement
U24-CA76518 from the National Cancer Institute
(NCI), the National Heart, Lung and Blood Institute
(NHLBI) and the National Institute of Allergy and In-
fectious Diseases (NIAID) and a Grant/Cooperative
Agreement 5U01HL069294 from NHLBI and NCI.REFERENCES
1. Gajewski JL, Lemaistre CF, Silver SM, et al. Impending
challenges in the hematopoietic stem cell transplant physician
workforce. Biol Blood Marrow Transplant. 2009;15:1493-1501.
2. Schriber JR, Anasetti C, Heslop HE, Leahigh AK. Preparing for
growth: current capacity and challenges in hematopoietic stem
cell transplantation programs. Biol Blood Marrow Transplant.
2010;16:595-597.
3. BallenKK,KingRJ, Chitphakdithai P, et al. The nationalmarrow
donor program 20 years of unrelated donor hematopoietic cell
transplantation. Biol Blood Marrow Transplant. 2008;14:2-7.
4. Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of
unrelated donor hematopoietic cell transplantation for adult
recipients facilitated by the National Marrow Donor Program.
Biol Blood Marrow Transplant. 2008;14:8-15.
5. MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of
unrelated donor bone marrow transplantation for pediatric acute
leukemia facilitated by the National Marrow Donor Program.
Biol Blood Marrow Transplant. 2008;14:16-22.
6. Majhail NS, Omondi NA, Denzen E, Murphy EA, Rizzo JD.
Access to hematopoietic cell transplantation in the United States.
Biol Blood Marrow Transplant. 2010;16:1070-1075.
